(Q35130093)

6 August 2017

1 reference

title

Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney (English)

1 reference

6 August 2017

author

Robert William Schrier

2

object named as

Robert W Schrier

1 reference

6 August 2017

1

Joshua M. Thurman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12753883

3 January 2024

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0002934303000901?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00090-1

https://api.elsevier.com/content/article/PII:S0002934303000901?httpAccept=text/plain

3 January 2024

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00090-1

American Journal of Medicine

3 January 2024

published in

1 reference

6 August 2017

volume

114

1 reference

6 August 2017

issue

7

1 reference

6 August 2017

page(s)

588-598

1 reference

The renin-angiotensin-aldosterone system: a specific target for hypertension management

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Aldosterone in progressive renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

The role of the AT2 receptor in hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Angiotensin II type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Reactive Hyperreninemia Is a Major Determinant of Plasma Angiotensin II During ACE Inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Determinants of angiotensin II generation during converting enzyme inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Angiotensin II-induced hypertension in bradykinin B2 receptor knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

The renin-angiotensin system and fibrinolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Targeting TGF-β overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Pathophysiology of Progressive Nephropathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Nephropathy in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effects of Converting-Enzyme Inhibition on Barrier Function in Diabetic Glomerulopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

The effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a pooled analysis of individual-patient data from 11 randomized, controlled trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effects of Losartan on a Background of Hydrochlorothiazide in Patients With Hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Does the antihypertensive response to angiotensin converting enzyme inhibition predict the antihypertensive response to angiotensin receptor antagonism?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Antiproteinuric effect of Losartan in patients with chronic renal diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Add-on angiotensin receptor blockade with maximized ACE inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Dosing angiotensin II blockers—beyond blood pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

From tissue angiotensin converting enzyme inhibition to antihypertensive effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900090-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure

19

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00090-1

Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients

3 January 2024

21

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00090-1

Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function

3 January 2024

31

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00090-1

Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes

3 January 2024

61

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(03)00090-1

3 January 2024

Identifiers

1 reference

6 August 2017

1 reference